CASE REPORT article
Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1608589
Trastuzumab Deruxtecan for Brain Metastatic Squamous Lung Carcinoma with Immune-Related Hypophysitis: A Case Report
Provisionally accepted
- West China School of Medicine, West China Hospital, Sichuan University, Chengdu, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Immunotherapy is an important part of the first-line treatment for lung squamous cell carcinoma (LUSC) in the current guidelines. However, in case when patients experience immunotherapy-related adverse reactions, immunotherapy may be discontinued. Antibody-drug conjugates (ADCs) may be an alternative treatment if the patient harbors actionable mutations. Herein, we present a case of brain metastatic LUSC harboring HER2 mutation who experienced hypophysitis after immunotherapy. This patient benefited from Trastuzumab Deruxtecan (T-DXd) after discontinuing immunotherapy. Therefore, T-DXd may be an alternative treatment option for LUSC patients with HER2 mutation who are unable to continue immunotherapy.
Keywords: Antibody-drug conjugates, targeted therapy, Immunotherapy, immune-related hypophysitis, Immune-related adverse events
Received: 09 Apr 2025; Accepted: 01 Sep 2025.
Copyright: © 2025 Xu, Gan, Zhang, Yang, LIu, Li, Wang and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Kaige Wang, West China School of Medicine, West China Hospital, Sichuan University, Chengdu, China
Dan Liu, West China School of Medicine, West China Hospital, Sichuan University, Chengdu, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.